Spread momentum continues unabated. Of note, CanSino's vaccine approval is getting no friends as the stock is down nearly 25% in 2 weeks and 29% in four. Negative alpha for a second week.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.